Consistent with our finding that napabucasin sensitizes esophageal cancer cells to CRT, Ebbing and colleagues recently demonstrated that stroma cell-derived IL-6 mediates CRT resistance of esophageal adenocarcinomas, which could be reverted by inhibition of IL-6 [44]. The gene discussed is IL6; the disease is esophageal cancer.